中华临床实验室管理电子杂志
中華臨床實驗室管理電子雜誌
중화림상실험실관리전자잡지
2014年
1期
16-20
,共5页
利奈唑胺%葡萄球菌%耐药机制
利奈唑胺%葡萄毬菌%耐藥機製
리내서알%포도구균%내약궤제
Linezolid%Staphylococci%Resistance mechanisms
利奈唑胺是第一个噁唑烷酮类抗菌药物，通过与细菌核糖体50S亚单位作用，抑制起始复合物的形成，而抑制细菌蛋白质合成。对葡萄球菌、链球菌、肠球菌等革兰阳性菌有很强的抗菌作用。目前，国内外已出现耐药葡萄球菌，耐药情况且呈上升趋势，特别是凝固酶阴性的葡萄球菌值得重视。耐药机制主要是细菌核糖体23S rRNA第V功能区基因突变，CFR基因的获得，编码50S核糖体蛋白L3、L4、L22的rplC、rplD、rplV的基因突变，23S rRNA修饰改变导致的耐药，LmrS多药外排泵，ABC蛋白过度表达等。
利奈唑胺是第一箇噁唑烷酮類抗菌藥物，通過與細菌覈糖體50S亞單位作用，抑製起始複閤物的形成，而抑製細菌蛋白質閤成。對葡萄毬菌、鏈毬菌、腸毬菌等革蘭暘性菌有很彊的抗菌作用。目前，國內外已齣現耐藥葡萄毬菌，耐藥情況且呈上升趨勢，特彆是凝固酶陰性的葡萄毬菌值得重視。耐藥機製主要是細菌覈糖體23S rRNA第V功能區基因突變，CFR基因的穫得，編碼50S覈糖體蛋白L3、L4、L22的rplC、rplD、rplV的基因突變，23S rRNA脩飾改變導緻的耐藥，LmrS多藥外排泵，ABC蛋白過度錶達等。
리내서알시제일개오서완동류항균약물，통과여세균핵당체50S아단위작용，억제기시복합물적형성，이억제세균단백질합성。대포도구균、련구균、장구균등혁란양성균유흔강적항균작용。목전，국내외이출현내약포도구균，내약정황차정상승추세，특별시응고매음성적포도구균치득중시。내약궤제주요시세균핵당체23S rRNA제V공능구기인돌변，CFR기인적획득，편마50S핵당체단백L3、L4、L22적rplC、rplD、rplV적기인돌변，23S rRNA수식개변도치적내약，LmrS다약외배빙，ABC단백과도표체등。
Linezolid is the ifrst oxazolidinone antibiotic. It inhibits protein synthesis through binding to the 50S ribosomal subunit and imperiling the formation of initial complex. It has antibacterial function to many Gram-positive bacteria, includingStaphylococci,Streptococci andEnterococci. Now, the Staphylococci resistant to Linezolid have been reported all over the world and the trend of resistance is increasing, especially for coagulase-negativeStaphylococci. The resistance mechanisms have been mainly characterized: mutations in the domain V region of 23S rRNA genes, acquisition of the ribosomal methyltransferase gene CFR, mutations in the rplC, rplD, rplV gene encoding the 50S ribosomal protein L3, L4, L22 modiifcations of 23S rRNA multidrug eflfux pump LmrS and overexpression of an ABC transporter and so on.
